Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota

Although anticancer therapy with immune checkpoint blockers has seen unprecedented success, it fails to control neoplasia in most patients and often causes immune-related adverse events (irAEs). Our recent research shows the immunostimulatory and antitumor effects of CTLA-4 blockade depend on distin...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncoimmunology 2017-01, Vol.6 (1), p.e1132137-e1132137
Hauptverfasser:	Pitt, Jonathan M., Vétizou, Marie, Gomperts Boneca, Ivo, Lepage, Patricia, Chamaillard, Mathias, Zitvogel, Laurence
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-CTLA-4 Author's View Bacteroides cancer ipilimumab Life Sciences microbiome microbiota T cell
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	e1132137
container_issue	1
container_start_page	e1132137
container_title	Oncoimmunology
container_volume	6
creator	Pitt, Jonathan M. Vétizou, Marie Gomperts Boneca, Ivo Lepage, Patricia Chamaillard, Mathias Zitvogel, Laurence
description	Although anticancer therapy with immune checkpoint blockers has seen unprecedented success, it fails to control neoplasia in most patients and often causes immune-related adverse events (irAEs). Our recent research shows the immunostimulatory and antitumor effects of CTLA-4 blockade depend on distinct Bacteroides species of the gut microbiota, signifying novel approaches to improve such immunotherapies.
doi_str_mv	10.1080/2162402X.2015.1132137
format	Article
fullrecord	<record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_01602605v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1868695742</sourcerecordid><originalsourceid>FETCH-LOGICAL-c502t-4d5ffa58a0ffc10987cb697ffb92e23a8be8e6e8459acbe2a7fe833e71bdd1dd3</originalsourceid><addsrcrecordid>eNp9Uc2L1DAUL6K4y7p_gtKjHmbMR5umF3FZVlcY8KLgLbymL9O4aTKm6cjc_NNNmdlBPRgIebz3-yDvVxQvKVlTIslbRgWrCPu2ZoTWa0o5o7x5Ulwu_dUyeHquKb0orqfpO8lHkFrw9nlxwSRtGy7IZfHrzg_gtfXbMg1Yame91eBKHfYYYYsl-D7flJteYyzRmFzqQxlMacdx9pkzoH7YBetT2bmgH6DHrBXDvB3KEbzdzQ6SDX6hLB7bOZWj1TF0NiR4UTwz4Ca8Pr1XxdcPd19u71ebzx8_3d5sVromLK2qvjYGagnEGE1JKxvdibYxpmsZMg6yQ4kCZVW3oDtk0BiUnGNDu76nfc-vindH3d3cjdhr9CmCU7toR4gHFcCqvyfeDmob9qpmkotKZIE3R4HhH9r9zUYtPUIFYXnFe5qxr09mMfyYcUpqtJNG58BjmCdFpZCirZuKZWh9hOaFTFNEc9amRC1hq8ew1RK2OoWdea_-_M-Z9RhtBrw_Aqw3IY7wM0TXqwQHF6KJS-aT4v_3-A36t70f</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1868695742</pqid></control><display><type>article</type><title>Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota</title><source>PubMed Central</source><creator>Pitt, Jonathan M. ; Vétizou, Marie ; Gomperts Boneca, Ivo ; Lepage, Patricia ; Chamaillard, Mathias ; Zitvogel, Laurence</creator><creatorcontrib>Pitt, Jonathan M. ; Vétizou, Marie ; Gomperts Boneca, Ivo ; Lepage, Patricia ; Chamaillard, Mathias ; Zitvogel, Laurence</creatorcontrib><description>Although anticancer therapy with immune checkpoint blockers has seen unprecedented success, it fails to control neoplasia in most patients and often causes immune-related adverse events (irAEs). Our recent research shows the immunostimulatory and antitumor effects of CTLA-4 blockade depend on distinct Bacteroides species of the gut microbiota, signifying novel approaches to improve such immunotherapies.</description><identifier>ISSN: 2162-4011</identifier><identifier>ISSN: 2162-402X</identifier><identifier>EISSN: 2162-402X</identifier><identifier>DOI: 10.1080/2162402X.2015.1132137</identifier><identifier>PMID: 28197360</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>Anti-CTLA-4 ; Author's View ; Bacteroides ; cancer ; ipilimumab ; Life Sciences ; microbiome ; microbiota ; T cell</subject><ispartof>Oncoimmunology, 2017-01, Vol.6 (1), p.e1132137-e1132137</ispartof><rights>2017 Taylor & Francis Group, LLC 2017</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><rights>2017 Taylor & Francis Group, LLC 2017 Taylor & Francis Group, LLC</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c502t-4d5ffa58a0ffc10987cb697ffb92e23a8be8e6e8459acbe2a7fe833e71bdd1dd3</citedby><cites>FETCH-LOGICAL-c502t-4d5ffa58a0ffc10987cb697ffb92e23a8be8e6e8459acbe2a7fe833e71bdd1dd3</cites><orcidid>0000-0003-1596-0998 ; 0000-0001-8122-509X ; 0000-0002-9501-6771</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5283646/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5283646/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28197360$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-01602605$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Pitt, Jonathan M.</creatorcontrib><creatorcontrib>Vétizou, Marie</creatorcontrib><creatorcontrib>Gomperts Boneca, Ivo</creatorcontrib><creatorcontrib>Lepage, Patricia</creatorcontrib><creatorcontrib>Chamaillard, Mathias</creatorcontrib><creatorcontrib>Zitvogel, Laurence</creatorcontrib><title>Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota</title><title>Oncoimmunology</title><addtitle>Oncoimmunology</addtitle><description>Although anticancer therapy with immune checkpoint blockers has seen unprecedented success, it fails to control neoplasia in most patients and often causes immune-related adverse events (irAEs). Our recent research shows the immunostimulatory and antitumor effects of CTLA-4 blockade depend on distinct Bacteroides species of the gut microbiota, signifying novel approaches to improve such immunotherapies.</description><subject>Anti-CTLA-4</subject><subject>Author's View</subject><subject>Bacteroides</subject><subject>cancer</subject><subject>ipilimumab</subject><subject>Life Sciences</subject><subject>microbiome</subject><subject>microbiota</subject><subject>T cell</subject><issn>2162-4011</issn><issn>2162-402X</issn><issn>2162-402X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9Uc2L1DAUL6K4y7p_gtKjHmbMR5umF3FZVlcY8KLgLbymL9O4aTKm6cjc_NNNmdlBPRgIebz3-yDvVxQvKVlTIslbRgWrCPu2ZoTWa0o5o7x5Ulwu_dUyeHquKb0orqfpO8lHkFrw9nlxwSRtGy7IZfHrzg_gtfXbMg1Yame91eBKHfYYYYsl-D7flJteYyzRmFzqQxlMacdx9pkzoH7YBetT2bmgH6DHrBXDvB3KEbzdzQ6SDX6hLB7bOZWj1TF0NiR4UTwz4Ca8Pr1XxdcPd19u71ebzx8_3d5sVromLK2qvjYGagnEGE1JKxvdibYxpmsZMg6yQ4kCZVW3oDtk0BiUnGNDu76nfc-vindH3d3cjdhr9CmCU7toR4gHFcCqvyfeDmob9qpmkotKZIE3R4HhH9r9zUYtPUIFYXnFe5qxr09mMfyYcUpqtJNG58BjmCdFpZCirZuKZWh9hOaFTFNEc9amRC1hq8ew1RK2OoWdea_-_M-Z9RhtBrw_Aqw3IY7wM0TXqwQHF6KJS-aT4v_3-A36t70f</recordid><startdate>20170102</startdate><enddate>20170102</enddate><creator>Pitt, Jonathan M.</creator><creator>Vétizou, Marie</creator><creator>Gomperts Boneca, Ivo</creator><creator>Lepage, Patricia</creator><creator>Chamaillard, Mathias</creator><creator>Zitvogel, Laurence</creator><general>Taylor & Francis</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1596-0998</orcidid><orcidid>https://orcid.org/0000-0001-8122-509X</orcidid><orcidid>https://orcid.org/0000-0002-9501-6771</orcidid></search><sort><creationdate>20170102</creationdate><title>Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota</title><author>Pitt, Jonathan M. ; Vétizou, Marie ; Gomperts Boneca, Ivo ; Lepage, Patricia ; Chamaillard, Mathias ; Zitvogel, Laurence</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c502t-4d5ffa58a0ffc10987cb697ffb92e23a8be8e6e8459acbe2a7fe833e71bdd1dd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Anti-CTLA-4</topic><topic>Author's View</topic><topic>Bacteroides</topic><topic>cancer</topic><topic>ipilimumab</topic><topic>Life Sciences</topic><topic>microbiome</topic><topic>microbiota</topic><topic>T cell</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pitt, Jonathan M.</creatorcontrib><creatorcontrib>Vétizou, Marie</creatorcontrib><creatorcontrib>Gomperts Boneca, Ivo</creatorcontrib><creatorcontrib>Lepage, Patricia</creatorcontrib><creatorcontrib>Chamaillard, Mathias</creatorcontrib><creatorcontrib>Zitvogel, Laurence</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncoimmunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pitt, Jonathan M.</au><au>Vétizou, Marie</au><au>Gomperts Boneca, Ivo</au><au>Lepage, Patricia</au><au>Chamaillard, Mathias</au><au>Zitvogel, Laurence</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota</atitle><jtitle>Oncoimmunology</jtitle><addtitle>Oncoimmunology</addtitle><date>2017-01-02</date><risdate>2017</risdate><volume>6</volume><issue>1</issue><spage>e1132137</spage><epage>e1132137</epage><pages>e1132137-e1132137</pages><issn>2162-4011</issn><issn>2162-402X</issn><eissn>2162-402X</eissn><abstract>Although anticancer therapy with immune checkpoint blockers has seen unprecedented success, it fails to control neoplasia in most patients and often causes immune-related adverse events (irAEs). Our recent research shows the immunostimulatory and antitumor effects of CTLA-4 blockade depend on distinct Bacteroides species of the gut microbiota, signifying novel approaches to improve such immunotherapies.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>28197360</pmid><doi>10.1080/2162402X.2015.1132137</doi><orcidid>https://orcid.org/0000-0003-1596-0998</orcidid><orcidid>https://orcid.org/0000-0001-8122-509X</orcidid><orcidid>https://orcid.org/0000-0002-9501-6771</orcidid><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 2162-4011
ispartof	Oncoimmunology, 2017-01, Vol.6 (1), p.e1132137-e1132137
issn	2162-4011 2162-402X 2162-402X
language	eng
recordid	cdi_hal_primary_oai_HAL_hal_01602605v1
source	PubMed Central
subjects	Anti-CTLA-4 Author's View Bacteroides cancer ipilimumab Life Sciences microbiome microbiota T cell
title	Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T05%3A46%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Enhancing%20the%20clinical%20coverage%20and%20anticancer%20efficacy%20of%20immune%20checkpoint%20blockade%20through%20manipulation%20of%20the%20gut%20microbiota&rft.jtitle=Oncoimmunology&rft.au=Pitt,%20Jonathan%20M.&rft.date=2017-01-02&rft.volume=6&rft.issue=1&rft.spage=e1132137&rft.epage=e1132137&rft.pages=e1132137-e1132137&rft.issn=2162-4011&rft.eissn=2162-402X&rft_id=info:doi/10.1080/2162402X.2015.1132137&rft_dat=%3Cproquest_hal_p%3E1868695742%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1868695742&rft_id=info:pmid/28197360&rfr_iscdi=true